A mutation in a nuclear receptor (NR1H3) gene was detected in a familial, progressive form of multiple sclerosis (PPMS) . Further analyses showed a significant association between a common NR1H3 variant in PPMS patients and loss of function for the encoded protein.
In the article ''Nuclear receptor NR1H3 in familial multiple sclerosis,'' a family presented with a rare form of progressive MS (Wang et al., 2016) . Because of the known familial incidence, the authors used exome-sequencing analysis on two related family members to locate a possible rare variant, pathogenic mutation (see Figure 1) . Once rare variants were identified using the affected family and healthy controls, analysis on a case-control series verified one of these variants, the p.Arg415Gln mutation, differed in frequency between controls and MS patients. The p.Arg415Gln mutation subsequently was identified in a separate, unrelated family with several members diagnosed with MS. Haplotype analyses of the two families confirmed shared ancestry. Linkage analysis of the two families produced a maximum LOD score of 2.20, which is suggestive of linkage, and the level of homologous conservation was high, supporting pathogenicity of this mutation.
To follow up the NR1H3 p.Arg415Gln result, common variants in NR1H3 were assessed in a MS case-control series to evaluate disease risk. None of the common variants significantly associated with MS until the population was stratified by MS clinical course (relapse-remitting [RRMS] versus primary progressive [PPMS] ). A significant association between one SNP, rs2279238, and a trend for association with two other SNPs and PPMS were detected, whereas no association was observed in the RRMS patients. The significant association of rs2279238 and PPMS confers a 1.35-fold increased risk of developing primary progressive MS. The authors then evaluated whether the p.Arg415Gln mutation disrupted heterodimerization of the LXRA protein to associated proteins and transcriptional activation of target genes. The mutation results in a loss of function of the LXRA protein and impaired transcriptional regulation. Protein expression analysis revealed that mutant LXRA alters gene expression profiles, suggesting a disruption in transcriptional regulation as one of the mechanisms underlying MS pathogenesis. The pathway including LXRA is suggested to play a critical role in myelination, hence the interest in this key finding (Makoukji et al., 2011; Shackleford et al., 2013; Meffre et al., 2015) . The authors state this study indicates that pharmacological activation of LXRA or its targets may lead to effective treatments for the highly debilitating and currently untreatable progressive phase of MS.
Cholesterol synthesis and metabolism have been implicated in MS pathology for almost a century (Zhornitsky et al., 2016) . Cholesterol and related molecules have the potential to be used clinically as biomarkers of treatment and disease outcomes in MS. It also remains unclear whether the relationship between cholesterol and MS disease outcomes is causal. A more recent study by the authors of the current study found an association with another gene in the cholesterol pathway, cholesterol 25-hydroxlyase, again segregating out the PPMS disease course versus the RRMS (Forwell et al., 2016) . This enzyme synthesizes cholesterol into the oxysterol, 25-hydroxycholesterol; oxysterols are natural ligands for LXRs and have been shown to inhibit peripheral myelin gene expression in Schwann cells (Makoukji et al., 2011) . Nuclear hormone receptors such as LXRs were altered in some populations of MS patients. Lower LXRA mRNA expression was detected in a Swedish population, but not in a Sardinian population; however, the patients used for the study had relapsingremitting MS, not a progressive clinical course (Liu et al., 2005) . It would be interesting to investigate whether different geographic populations and/or clinical courses would yield different results for genes in the cholesterol pathways and provide a better understanding of these molecular mechanisms in MS.
One caveat in the current study is the finding of the mutation in unaffected carriers and one sibling, indicating penetrance is incomplete for the NR1H3 p.Arg415Gln mutation, and other genetic or environmental factors may play a role in the onset of progressive MS. This is not too surprising, as MS is a complex heterogeneous disease, and many genes and environmental factors have been implicated in disease risk and clinical course Fagnani et al., 2015; Gourraud et al., 2012) . Clinical information was not available for unaffected family members, suggesting that assessment and follow-up of these individuals would be supportive of the data. As the authors pointed out, assessment of NR1H3 variants and replication of the analyses in different populations and other affected families could confirm whether the mutation is in fact associated with the onset of MS, particularly the progressive clinical course.
Relapsing-remitting MS and progressive MS display different pathological features, so it is not surprising that the genetics of the disease courses would have some different underlying risk factors as well as overlapping risk factors.
While the pathophysiology in relapsingremitting MS is dominated by the inflammatory response, in progressive MS, no single pathogenic process has emerged so far (Mahad et al., 2015; Salvetti et al., 2015) . Progressive MS is dominated by gradual disability caused by neurodegenerative processes and axonal loss, leading ultimately to brain atrophy. It has been hypothesized that several mechanisms contribute to the accumulation of disability in progressive MS, including chronic microglial activation, mitochondrial dysfunction, compartmentalization of inflammation behind an intact bloodbrain barrier, and formation of ectopic lymphoid tissue in the meninges (Giacalone et al., 2015; Mahad et al., 2015) . Genome-wide association studies have revealed the complex genetics underlying MS susceptibility, with different signals in the major histocompatibility complex (MHC) region and 110 non-human leukocyte antigen (HLA) genetic variants and have highlighted inflammatory-immunological mechanisms as the key drivers of MS pathology. Many genetic studies did not stratify patient populations or exclusively used patients with relapse-remitting MS in their analyses. About 5%-15% of MS patients are diagnosed with primary progressive form of MS at onset; therefore, the available number of cases is lower than for relapsing-remitting MS, which lowers statistical power to detect significant small genetic effects also hindering analyses for progressive MS. However, even with all of these identified genes, only 28%-37% of the genetic heritability has been accounted for in MS (Beecham et al., 2013; Khankhanian et al., 2015) . Some believe that nonhypothesis-driven investigations may enhance the understanding of MS disease pathophysiology to the extent that they could lead to the identification of therapies in the absence of a complete understanding of the pathologic process . A systems biology approach could be used to detect other pathways and networks involved in the biological mechanisms influencing MS onset and severity to find potential therapeutic targets (Giacalone et al., 2015) .
In conclusion, the authors have demonstrated how valuable family pedigrees can be in the discovery of key genetic underpinnings of complex phenotypes, and the extension of these findings to the broader sporadic forms of MS is the ultimate proof of the value of Mendelian phenocopies in gaining better understanding of the more common complex forms of the disease.
